APC
CTXR icon

Aspire Private Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Aspire Private Capital’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$150 – 259
2024
Q3 		$150 Hold
12
– – ﹤0.01% 645
2024
Q2 		$175 Hold
12
– – ﹤0.01% 657
2024
Q1 		$269 Hold
12
– – ﹤0.01% 675
2023
Q4 		$226 Hold
12
– – ﹤0.01% 671
2023
Q3 		$205 Hold
12
– – ﹤0.01% 671
2023
Q2 		$360 Hold
12
– – ﹤0.01% 622
2023
Q1 		$351 Hold
12
– – ﹤0.01% 609
2022
Q4 		$237 Hold
12
– – ﹤0.01% 621
2022
Q3 		$0 Hold
12
– – ﹤0.01% 619
2022
Q2 		$0 Buy
+12
New +$329 ﹤0.01% 611

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Aspire Private Capital's CTXR Position: Q4 2024 in Review

Aspire Private Capital sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 12 shares — an estimated $150 sold.

Aspire Private Capital first reported a position in CTXR in Q2 2022 and held it in 10 quarters. The position peaked at $360 in Q2 2023. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Aspire Private Capital reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Aspire Private Capital sold 12 Citius Pharmaceuticals shares in Q4 2024, an estimated $150.
  • Aspire Private Capital first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Aspire Private Capital's Citius Pharmaceuticals position peaked at $360 in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.